Lesson
Recognize the Host Before the Organism
Pneumocystis jirovecii causes pneumonia when cell-mediated defense is impaired. Host context changes risk, tempo, inflammatory burden, and the prevention strategy.
- P. jirovecii
- Cell-mediated immunity
- HIV
- Transplant and malignancy
- Alveolar injury
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Place the organism correctly
P. jirovecii is a human fungal pathogen. The clinical syndrome is still commonly abbreviated PCP. Exposure is widespread, and disease reflects acquisition or reactivation in a susceptible host rather than ordinary bacterial-pneumonia risk.
Identify HIV-associated risk
About 90 percent of HIV-associated cases occur with CD4 counts below 200 cells per cubic millimeter, with the greatest contemporary burden in people who are unaware of HIV, are outside continuous care, or have advanced immunosuppression.
Build a separate non-HIV risk model
Transplant, hematologic malignancy, lymphocyte-depleting therapy, prolonged or combined immunosuppression, and selected inflammatory-disease regimens can create risk. Use the current specialty protocol and complete regimen rather than applying HIV CD4 rules universally.
Connect inflammation to gas exchange
Organisms and inflammatory material occupy alveolar spaces and impair diffusion. Exertional desaturation can precede resting hypoxemia, and severe disease can exist despite a quiet early lung examination.
Quick check
Lesson
Move From Suspicion to Respiratory Evidence
No single symptom, image, biomarker, or molecular result proves PCP. Diagnosis joins a compatible host and syndrome to adequate respiratory evidence while preserving competing causes.
- Subacute syndrome
- Ground-glass attenuation
- Induced sputum
- BAL
- PCR and beta-D-glucan
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Recognize the pattern
In HIV, progressive dyspnea, fever, nonproductive cough, chest discomfort, and exertional desaturation often evolve over days to weeks. Non-HIV disease may be more abrupt and severe. Pneumothorax or diffuse ground-glass disease in a susceptible host raises concern.
Escalate imaging appropriately
Chest radiography often shows diffuse bilateral interstitial or ground-glass infiltrates, but it can be normal early. Thin-section CT usually reveals patchy or diffuse ground-glass attenuation, while nodules, large effusions, or focal cavitation should widen the differential.
Obtain an adequate respiratory specimen
Definitive diagnosis requires organisms in induced sputum, BAL fluid, or tissue. Spontaneously expectorated sputum has low sensitivity. BAL generally has greater diagnostic yield and can evaluate concurrent infection or malignancy.
Interpret adjunctive tests honestly
PCR is highly sensitive but can detect colonization. Quantitative burden can help, but standardized cutoffs remain difficult. Low beta-D-glucan makes PCP less likely in the right context, while elevation is nonspecific and can have other fungal, dialysis, or drug causes.
Quick check
Lesson
Calculate Severity From Gas Exchange
Room-air PaO2 and the alveolar-arterial oxygen gradient classify pulmonary impairment and determine adjunctive-corticosteroid eligibility.
- PaO2
- PAO2
- A-a gradient
- Room air
- Steroid threshold
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Use a valid arterial sample
Record FiO2 and oxygen device when the ABG is drawn. The NIH room-air thresholds cannot be copied onto a sample obtained after supplemental oxygen without an appropriate physiologic interpretation.
Estimate alveolar oxygen
At sea level on room air, PAO2 is commonly estimated as 150 minus PaCO2 divided by 0.8. The A-a gradient equals estimated PAO2 minus measured PaO2. Altitude, FiO2, barometric pressure, and respiratory quotient can require the complete alveolar gas equation.
Classify the gradient
NIH describes mild hypoxemia as room-air PaO2 at least 70 or A-a below 35, moderate disease as A-a 35 to below 45, and severe disease as A-a at least 45. Clinical instability can outweigh a reassuring single number.
Trigger adjunctive steroids
For HIV-associated PCP, room-air PaO2 below 70 or A-a at least 35 is sufficient. Either criterion qualifies. Capture the value early so treatment escalation is not delayed.
Quick check
Lesson
Dose the Preferred Therapy by Trimethoprim
TMP-SMX blocks sequential microbial folate steps. Active PCP requires high, weight-based exposure expressed by the trimethoprim component, not a routine outpatient tablet schedule.
- Sequential folate blockade
- TMP component
- 15 to 20 mg/kg/day
- Renal adjustment
- Toxicity surveillance
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Trace the two targets
Sulfamethoxazole competes with PABA at dihydropteroate synthase. Trimethoprim inhibits dihydrofolate reductase downstream. Sequential blockade limits tetrahydrofolate needed for organism growth.
Calculate active treatment exposure
Current NIH treatment uses TMP 15 to 20 mg per kg per day with SMX 75 to 100 mg per kg per day. Divide the TMP target every six or eight hours for IV treatment or into three oral doses for mild-to-moderate disease.
Make the product conversion visible
One single-strength tablet contains 80 mg TMP with 400 mg SMX. One double-strength tablet contains 160 mg TMP with 800 mg SMX. Verify liquid or IV concentration, measurable amount, final volume, infusion, and renal adaptation.
Monitor the exposure system
Trend CBC, platelets, creatinine clearance, urine output, potassium, sodium, liver tests, rash, fever, mucosa, interacting drugs, and clinical response. A creatinine rise can reflect inhibited secretion, true kidney injury, or both.
Quick check
Lesson
Secure Early Exposure in Moderate-to-Severe Disease
Hypoxemic PCP requires dependable systemic exposure, adjunctive corticosteroid review, close respiratory support, and a complete 21-day active course.
- IV TMP-SMX
- Clindamycin plus primaquine
- IV pentamidine
- Oral transition
- Twenty-one days
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Use preferred intravenous therapy
For moderate-to-severe HIV-associated PCP, use TMP 15 to 20 mg per kg per day with SMX 75 to 100 mg per kg per day intravenously in divided doses every six or eight hours before renal adjustment.
Choose a valid alternative
Primaquine 30 mg base orally daily plus clindamycin intravenously or orally, or pentamidine 4 mg per kg intravenously daily, are current alternatives. G6PD activity, kidney function, glucose, electrolytes, ECG, blood pressure, and route feasibility shape the decision.
Transition only after improvement
A switch from IV to oral TMP-SMX can follow clinical improvement when gastrointestinal absorption, adherence, renal dosing, monitoring, and follow-up are reliable. A calendar date alone does not prove readiness.
Complete the course
All current NIH treatment regimens continue for 21 days. Document effective start, missed doses, toxicity-driven switches, response, and the immediate handoff to secondary prophylaxis.
Quick check
Lesson
Treat Mild-to-Moderate Disease Without Underexposure
Stable mild-to-moderate PCP can use oral therapy, but severity, absorption, food, G6PD status, renal function, adherence, and urgent follow-up still determine safety.
- Oral TMP-SMX
- Atovaquone
- Dapsone plus TMP
- Primaquine plus clindamycin
- Outpatient system
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Keep TMP-SMX first
Oral TMP-SMX uses the same TMP 15 to 20 mg per kg per day target in three divided doses. NIH also lists two double-strength tablets three times daily before renal adjustment.
Administer atovaquone with food
Atovaquone suspension 750 mg twice daily with food for 21 days is an alternative when TMP-SMX cannot be used. Shake the suspension gently. Poor intake, gastrointestinal disease, rifamycins, tetracycline, or metoclopramide can reduce exposure.
Protect against oxidant injury
Dapsone 100 mg daily plus TMP 15 mg per kg per day in three doses, or primaquine 30 mg base daily plus clindamycin, require normal G6PD activity and monitoring for hemolysis or methemoglobinemia.
Make outpatient care real
Confirm stable oxygenation, oral tolerance, medication access, laboratory timing, adherence, transport, clear return precautions, and a named clinician responsible for response review.
Quick check
Lesson
Use the Complete Corticosteroid Pathway
Adjunctive corticosteroids improve outcomes in eligible hypoxemic HIV-associated PCP when started with active therapy and delivered through the full 21-day schedule.
- PaO2 below 70
- A-a at least 35
- Within 72 hours
- Prednisone taper
- Methylprednisolone
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Start when either criterion is met
Use adjunctive corticosteroids for room-air PaO2 below 70 mmHg or A-a gradient at least 35 mmHg. Begin as soon as possible and ideally within 72 hours of starting anti-PCP therapy.
Write the complete prednisone schedule
Give prednisone 40 mg twice daily on days 1 to 5, 40 mg daily on days 6 to 10, and 20 mg daily on days 11 to 21. Put the dates and phase transitions into inpatient and discharge orders.
Convert intravenous therapy correctly
When oral prednisone is not feasible, IV methylprednisolone can be given at 80 percent of the corresponding prednisone dose. Reconvert deliberately when oral administration resumes.
Monitor benefit and harm
Track oxygenation, work of breathing, glucose, blood pressure, mental status, fluid, gastrointestinal symptoms, infection, and pregnancy-specific maternal and fetal parameters when applicable.
Quick check
Lesson
Make Every Alternative Safer Than the Failure It Replaces
Alternative PCP regimens trade one toxicity profile for another. G6PD testing, infusion design, absorption, metabolic surveillance, and interaction review are part of the treatment.
- Pentamidine
- Dapsone
- Primaquine
- Atovaquone
- Methemoglobinemia
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Control pentamidine infusion risk
Pentamidine 4 mg per kg intravenously daily is infused over at least 60 minutes and can be reduced to 3 mg per kg for toxicity. Do not use sodium chloride for initial reconstitution because precipitation can occur. Monitor blood pressure during and after infusion.
Monitor delayed metabolic toxicity
Pentamidine can cause nephrotoxicity, pancreatitis, severe hypotension, hypoglycemia, later hyperglycemia or diabetes, calcium and magnesium disturbances, cytopenias, liver injury, QT effects, and arrhythmia. Glucose monitoring continues after treatment.
Recognize oxidant injury
Check G6PD before dapsone or primaquine. New anemia, jaundice, cyanosis, saturation gap, headache, fatigue, or persistent apparent hypoxemia requires evaluation for hemolysis and methemoglobinemia.
Protect atovaquone absorption
Use the suspension with food, review gastrointestinal disease and interacting drugs, and monitor liver tests and response. It is not established for severe PCP or as salvage after TMP-SMX failure.
Quick check
Lesson
Prevent the First Episode With Current Risk Criteria
Primary prophylaxis in HIV follows CD4, ART, viral suppression, Toxoplasma serostatus, tolerance, and immune recovery rather than a permanent diagnosis label.
- CD4 below 200
- Daily TMP-SMX
- Toxoplasma status
- Stop criteria
- Restart criteria
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Start in the correct HIV context
For people not on ART or starting ART, begin prophylaxis when CD4 is below 200 cells per cubic millimeter. For people already on ART, current CD4 and detectable HIV RNA determine start or restart.
Use preferred daily therapy
Preferred prophylaxis is one TMP-SMX double-strength tablet daily or one single-strength tablet daily. Double-strength three times weekly is an alternative. TMP-SMX also protects against toxoplasmosis and some respiratory bacterial infections.
Preserve Toxoplasma protection
Atovaquone or dapsone plus pyrimethamine plus leucovorin can cover both PCP and toxoplasmosis. Dapsone alone and aerosolized or IV pentamidine should be limited to Toxoplasma-seronegative patients.
Stop and restart deliberately
Stop after CD4 rises from below 200 to at least 200 for at least three months on ART. Selected patients with CD4 100 to 200 and sustained undetectable HIV RNA for three to six months may also be considered. Restart below 100 regardless of RNA, or at 100 to 200 with detectable RNA.
Quick check
Lesson
Prevent Recurrence While Immunity Recovers
A prior PCP episode creates an immediate secondary-prophylaxis need, while ART and sustained immune recovery determine when prevention can safely stop.
- Prior PCP
- Immediate prophylaxis
- ART within two weeks
- Immune recovery
- IRIS
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Start without a gap
Begin secondary prophylaxis immediately after successful completion of the 21-day active course. Preferred regimens and most alternatives mirror primary prophylaxis, with Toxoplasma coverage and toxicity still considered.
Start ART promptly
If ART is not already active, begin within two weeks of PCP diagnosis when possible. Review resistance history, formulation, ICU delivery, absorption, interactions, adherence support, and access rather than delaying routinely until PCP therapy ends.
Stop after sustained recovery
Secondary prophylaxis can usually stop after CD4 rises from below 200 to at least 200 for at least three months on ART. Selected suppressed patients at 100 to 200 can be considered after three to six months.
Handle the high-CD4 exception
If PCP occurs above CD4 200 while the patient is already on ART, lifelong prophylaxis may be prudent. If it occurred above 200 while off ART, discontinuation can be considered after sustained viral suppression, although evidence is limited.
Quick check
Lesson
Do Not Confuse Inflammation, Toxicity, and Failure
Early respiratory worsening, dangerous drug toxicity, competing disease, underexposure, and true antimicrobial failure require different responses and different clocks.
- Early worsening
- Four to eight days
- ABG trajectory
- Competing disease
- Toxicity switch
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Expect an early inflammatory window
Without adjunctive corticosteroids, reversible deterioration can occur during the first three to five days as killed organisms amplify pulmonary inflammation. Reassess urgently, but do not declare efficacy failure from one early difficult day.
Use the current failure definition
Clinical failure is lack of improvement or worsening respiratory function documented by ABG after four to eight days of adequate therapy. Verify dose, renal adjustment, administration, absorption, and adherence before blaming resistance.
Reopen the differential
Evaluate bacterial, viral, fungal, or mycobacterial co-infection, malignancy, edema, embolism, pneumothorax, respiratory-support complications, and the original diagnosis. BAL should be strongly considered when uncertainty persists.
Act immediately on dangerous toxicity
The four-to-eight-day wait applies to efficacy, not life-threatening toxicity. Severe hypersensitivity, cytopenia, kidney or electrolyte injury, pancreatitis, arrhythmia, hypotension, hemolysis, or methemoglobinemia can require prompt regimen change.
Quick check
Lesson
Close the PCP Loop
A complete PCP plan moves from host and evidence through oxygenation, treatment, toxicity, immune restoration, recurrence prevention, and accountable follow-up.
- Pregnancy
- Non-HIV risk
- Complete plan
- Follow-up owner
- Educational boundary
Carry the verified input forward.
Carry the verified input forward.
Carry the verified input forward.
Own the next clinical action.
Use current pregnancy reasoning
TMP-SMX remains preferred for active PCP during pregnancy because maternal morbidity and mortality reduction outweigh potential exposure risk. Current guidance adds trimester-specific folic acid and fetal anatomy assessment rather than relying on obsolete pregnancy letters.
Keep non-HIV prevention specific
Use current oncology, transplant, rheumatology, or immune-therapy protocols. Evaluate the complete immunosuppressive regimen, duration, lymphocyte state, prior PCP, comorbidity, organ function, and local epidemiology.
Audit the complete plan
Verify host, diagnostic evidence, room-air oxygenation, regimen, TMP-based dose when used, route, renal function, G6PD, CBC, electrolytes, interactions, steroid eligibility, response, ART, 21-day duration, prophylaxis, and follow-up.
Keep education within its role
This module develops clinical reasoning and cannot diagnose or prescribe for an individual. Real PCP care requires current patient data, urgent respiratory assessment, institutional protocols, and accountable infectious-disease, HIV, pulmonary, pharmacy, and critical-care teams when indicated.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 208 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.